Zimmer Biomet (ZBH)
NYSE: ZBH · Health Care Equipment · Warsaw, IN
Our rating: Positive
Positive reaffirmed at $106.85, moderate conviction, November 5, 2026.
Breaks if: The Positive view breaks if free cash flow margin falls below 15% of revenue — from roughly 18% today — in any two of the next three quarterly filings, signaling that the cash-conversion story is eroding rather than holding steady under amortization load; or if year-over-year revenue growth decelerates below 4% for two consecutive quarters, implying the end-market tailwind is fading faster than demographic math alone would predict. The view would sharpen toward Conviction if FCF margin expands above 20% while revenue growth sustains above 7%, giving a materially cleaner risk-reward than the current picture offers.
Key figures
| Market value | $19.1B |
|---|---|
| Revenue, last 12 months | $8.6B |
| Net income, last 12 months | $767M |
| Free cash flow, last 12 months | $1.6B |
| Price to earnings | 24.9× |
| Free cash flow yield | 8.6% |
| Dividend yield | 0.9% |
| Operating margin | 13.6% |
| Return on equity | 6.0% |
| Beta to the S&P 500 | 0.34 |
| Volatility, annualized | 30.1% |
Reported quarters
| Quarter ending | Revenue | Year on year | Earnings per share | Free cash flow |
|---|---|---|---|---|
| September 30, 2026 | $2.1B | 3.1% | $1.00 | $484M |
| June 30, 2026 | $2.2B | 4.8% | $1.03 | $394M |
| March 31, 2026 | $2.1B | 9.3% | $1.22 | $323M |
| December 31, 2025 | $2.2B | 10.9% | $0.71 | $443M |
| September 30, 2025 | $2.0B | 9.7% | $1.16 | $364M |
| June 30, 2025 | $2.1B | 7.0% | $0.77 | $328M |
| March 31, 2025 | $1.9B | 1.1% | $0.91 | $338M |
| December 31, 2024 | $2.0B | 4.3% | $1.19 | $455M |
Three-model forecasts for the next quarter
Written November 21, 2026, before the report. Each settles from the SEC filing.
- Revenue for the quarter is at least $2.40B: Claude 28%, Gemini 45%, Mistral 22%
- Diluted earnings per share are at least $0.71: Claude 72%, Gemini 90%, Mistral 85%
- Free cash flow for the quarter is at least $0.44B: Claude 52%, Gemini 80%, Mistral 80%
10 ledger entries and 56 corporate events on record. Share price as of November 20, 2026. Research and education only. Not investment advice. Stoquity does not manage money or know your circumstances. Ratings, forecasts and lists are produced by software and AI models and can be wrong. Performance figures are hypothetical, measured on paper against a benchmark, and say nothing certain about the future.